Understand the source comparison
Cartalax Cartilage Bioregulation: Research Protocol Comparison
Cartalax Concentration/Dose 10–20 μM in culture medium 100–200 μg/kg body weight subcutaneous 7–14 mg/day (70 kg human) Dosing extrapolation from animal models is uncertain due to species differences in peptide metabolism; human trials have not established opt
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Cartalax Concentration/Dose
- 10–20 μM in culture medium
- 100–200 μg/kg body weight subcutaneous
- 7–14 mg/day (70 kg human)
- Dosing extrapolation from animal models is uncertain due to species differences in peptide metabolism; human trials have not established optimal dose
- Administration Route
- Direct addition to medium
- Subcutaneous injection
- Subcutaneous or oral with enteric coating
- Subcutaneous avoids first-pass degradation but oral delivery remains experimentally promising with appropriate formulation
- Treatment Duration
- 48–72 hours (acute studies)
- 30–60 days (chronic model)
- 8–12 weeks minimum for matrix remodeling
- Cartilage matrix turnover is exceptionally slow (6–12 month half-life for collagen type II); short-term studies may miss clinically meaningful effects
- Primary Outcome Measured
- Gene expression (qPCR), protein synthesis
- Histological grading, cartilage thickness
- Not yet established in clinical trials
- Biochemical markers (serum CTX-II, COMP) may provide earlier signals than imaging or functional outcomes
- Combination Therapy
- Often tested with IL-1β or TNF-α stress
- Typically monotherapy vs saline control
- Potentially synergistic with hyaluronic acid or PRP
- Mechanistic complementarity suggests combination approaches warrant investigation
- Evidence Quality
- Moderate (multiple independent labs)
- Limited (primarily Saint Petersburg Institute)
- None (no published Phase II/III trials)
- The absence of large-scale human trials is the critical gap; animal and in vitro data are hypothesis-generating only
- The most significant knowledge gap in Cartalax cartilage bioregulation research is the absence of double-blind, placebo-controlled human trials with validated clinical endpoints. Preclinical models demonstrate biological activity, but cartilage is notoriously difficult to study in humans. Imaging modalities like MRI can detect gross structural changes, but detecting early matrix composition shifts requires invasive biopsy or indirect biomarkers like serum levels of collagen type II C-telopeptide (CTX-II), which have high inter-individual variability.